I am bullish on (NYSE: UNH ), driven by the company’s diversified model seen in an impressive FY2024 growth outlook of between $450 billion and $455 billion for FY2025. Despite projected federal Medicaid budget cutsFirst Principles Partners is an equity research analyst specializing in technology, innovation, and sustainability investment. My unique approach, "First Principles," involves breaking down complex problems to their most basic elements in terms of financial and technology, enabling me to uncover ...

If you're seeking dividend income, bravo -- because dividends are hard to beat. Healthy and growing dividend-paying stocks will keep sending you cash, no matter whether the economy is booming or slumping. And that cash is handy not only for retirees. Younger investors can use it to just buy more shares of stock. One dividend payer to consider is UnitedHealth Group (UNH -0.64%), with a 2.8% dividend yield. Imagine you're seeking $1,000 in annual income from UnitedHealth stock. How many shares must you buy?We ...

智通财经6月19日电，摩根大通将联合健康目标股价从405美元上调至418美元。 ...

Core Insights - The selloff of UnitedHealth (NYSE: UNH) that began in May 2025 resulted in a nearly 50% loss of its market value, which has been extensively reported by financial media [1]. Company Analysis - UnitedHealth experienced a significant decline in market value, losing almost half of its worth during the selloff [1]. Industry Context - The healthcare sector, particularly companies like UnitedHealth, is facing volatility, as evidenced by the drastic market movements [1].

Core Insights - The healthcare sector is significantly influenced by major players like UnitedHealth Group and CVS Health, both of which integrate insurance and care delivery [1][2] - UnitedHealth's recent challenges include rising medical costs and regulatory shifts, while CVS is seen as a strong value play with a clear turnaround strategy [2] UnitedHealth Group (UNH) - UNH reported first-quarter revenues of $109.6 billion and adjusted net income of $6.6 billion, maintaining a 6% net margin [3] - The company missed earnings estimates once in the past four quarters, with an average surprise of 1.2% [4] - Medical costs surged 11.7% in the first quarter, following a 9.2% rise in 2024, with expectations of over 16% growth in 2025 [5] - UNH's pharmacy benefit manager, Optum Rx, may face regulatory challenges affecting pricing power [6] - The new CEO, Steve Hemsley, has pledged to rebuild shareholder trust after the company's first earnings miss in nearly two decades [7] CVS Health Corporation (CVS) - CVS reported first-quarter revenues of $94.6 billion and net income of $1.8 billion, with adjusted EPS of $2.25, beating last year's $1.31 by 31.6% [8][10] - The Health Care Benefits segment's medical benefit ratio improved to 87.3%, reflecting better cost control [8] - CVS has consistently beaten earnings estimates in the past four quarters, with an average surprise of 18.1% [9] - The company raised its 2025 EPS guidance to $6.00-$6.20, up from $5.75-$6.00, and anticipates $500 million in savings from retail store closures [10][14] - CVS's diversified model is showing momentum with rising retail script volumes and improved operating income across segments [12] Comparative Analysis - Zacks Consensus Estimates favor CVS, with upward revisions in EPS estimates, while UNH has seen multiple downward revisions [15] - CVS trades at a forward P/E of 10.31, compared to UNH's 12.98, indicating a more attractive risk-reward profile for CVS [16] - Year-to-date, UNH shares have dropped 39% due to medical cost concerns, while CVS shares have increased by 49.4% [18] Conclusion - UnitedHealth faces challenges with cost control and guidance uncertainties, while CVS is executing a successful turnaround with improving margins and positive analyst sentiment [21][22] - For investors seeking upside potential, CVS Health is positioned as the stronger investment option in the current healthcare landscape [22]

Hims & Hers Health shares rocketed higher over the last year, rewarding investors. When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity thanks to blockbuster drugs and widely recognized pharmacy management services. What does Oscar Health do, and why might it draw comparisons to Hims & Hers? When it comes to accessing patient care, consumers have a couple of optio ...

UnitedHealth Group (UNH 0.49%) is in the headlines again, this time, it's to announce that it is exiting Latin America. The announcement is just the latest in a series of news events in what has been a tumultuous year for the once-safe healthcare giant, whose shares are down a staggering 38% year to date as of June 13. There's been a flurry of bad news surrounding this business, including a change in its CEO last month. Does the company exiting Latin America signal more challenges ahead for the business, an ...

Let's explore what's going on at UnitedHealth right now and dig into the details on what's driving investors to run for the hills. From there, I'll draw some parallels from other businesses that remind me of UnitedHealth's current situation to help asses where the stock could be one year from now. Shares of UnitedHealth Group have sold off considerably this year, as bad news surrounding the company continues to pile up. UnitedHealth Group (UNH 0.39%) has been one of the more interesting case studies in the ...

Group 1: Lululemon Athletica - Lululemon Athletica is experiencing margin compression despite growth, leading to price target reductions from analysts [1][3] - The current stock price is $239.29, with a 12-month price forecast of $340.26, indicating a potential upside of 42.20% [1][2] - The company maintains an 18% operating margin, supporting a healthy balance sheet and business investment [3] Group 2: UnitedHealth Group - UnitedHealth Group's stock has faced significant declines due to regulatory, legal, and margin issues, resulting in drastic price target reductions [5][6] - The current stock price is $308.22, with a 12-month price forecast of $426.52, suggesting a potential upside of 38.38% [5][6] - Institutional ownership is high at approximately 87%, with solid buying activity in Q2, indicating potential stability [8] Group 3: Enphase Energy - Enphase Energy is challenged by potential cuts to subsidies for alternative energy under the Trump administration, impacting revenue and earnings outlook [10][11] - The current stock price is $33.80, with a 12-month price forecast of $67.07, indicating a potential upside of 98.41% [10] - Institutional interest is significant, with over 70% ownership, but recent selling trends suggest a continued downtrend unless favorable news emerges [12]

Key Takeaways UnitedHealth leans on Optum to offset pressures in its health benefits business. Optum's revenue growth outpaced UnitedHealthcare from 2022 to 2024. Optum contributed over half of UnitedHealth's total operating income last year.Yes, UnitedHealth Group Incorporated (UNH) is increasingly relying on its Optum business to drive growth and offset challenges in the health benefits segment, UnitedHealthcare. Optum has become the company’s primary growth engine, delivering stronger margins and faste ...